PRP and Orthobiologics in Ballwin, MO

I-270 NORTH

Two studies of the same treatment reach opposite conclusions. That is not a reason to dismiss it, and it is not a reason to believe the flattering one.

Getting here from Ballwin

I-270 north to Natural Bridge Road — around twenty-seven minutes, near the outer edge of our ring. Parking at the door.

Why the trials disagree

The literature on orthobiologics genuinely conflicts, and most of the conflict is explicable rather than mysterious. Studies differ in platelet dose by an order of magnitude, in whether white cells are included, in whether the injection was image-guided, and in whether any loading program ran alongside.

Pooling those into a single meta-analysis and reporting a null result tells you that a heterogeneous set of interventions averages to nothing. It does not tell you that a well-prepared, well-placed injection with a rehabilitation program does nothing.

Why the trials disagree sets that out in detail, and it is the most useful page on this site for anyone deciding whether to spend money here.

Dose is the variable nobody discloses

Outcome tracks platelet dose in the studies that report it, and a great many clinics do not know or will not say what dose their system produces.

It is a fair question to ask anywhere you are considering treatment. What PRP actually is covers what varies between systems and why two things both called PRP are not the same product.

What we publish and what we do not

We do not publish success rates from our own uncontrolled experience, because they would tell you nothing and would look impressive.

What we will give you is the evidence position for your specific indication and an honest estimate given your own findings.

What we would want asked of us

Who performs the injection, whether it is image-guided, what preparation and platelet dose, and what happens if it does not work. Four questions that separate most of this field.

We answer them in writing before treatment rather than after, and any clinic unwilling to is telling you something.

Cost is not evidence

Price varies enormously in this space and correlates with marketing rather than with preparation quality or outcome. An expensive product is not a better one.

Paying for treatment sets out what is and is not billable before anything is scheduled.

What a null result should change

Where the evidence genuinely does not support a treatment for an indication, we say so and do not offer it. That is a shorter list than the marketing implies and a longer one than enthusiasts admit.

Being able to name the indications where we would decline is the most honest signal a practice can give.

Placebo, and taking it seriously

Injection procedures carry a substantial placebo effect, which is why uncontrolled series look impressive. Any clinic quoting success rates from its own uncontrolled experience is telling you very little.

The counterweight is objective measurement — range, strength, function — recorded before and after rather than a satisfaction score.

What we do with all of that

Confirm the diagnosis, choose the preparation by tissue, place it under imaging, and pair it with loading. Then measure. If the measurements do not move, the plan changes rather than repeats.

What is injected is autologous — drawn from you, concentrated, and returned in the same visit. What PRP actually is covers the preparation, and PRP versus stem cells covers the products marketed at seminars, which are a different proposition and not one we offer.

The appointment itself

A first visit is about an hour: history, examination under load, and a reading of imaging you already have against what actually reproduces the pain. What to expect sets out the visit itself and the risks covers what can go wrong, which is a short list and not an empty one.

The ceiling nobody measures

Any honest account of who responds has to include the state of the person, not only the preparation used. The metabolic side covers the markers that predict it.

The subgroup problem, and why averages mislead here

A trial reports an average. When the population enrolled is heterogeneous — a mix of early and advanced disease, of tendon and joint, of active and sedentary — a real benefit confined to one subgroup is diluted by everyone it was never going to help, and the average comes back near zero.

That is not a hypothetical criticism. Several of the negative orthobiologic trials enrolled broadly and analyzed as one group, and the subgroup analyses that follow are treated as unreliable precisely because they were not planned in advance. Both positions are defensible, which is why the literature stays unsettled longer than either side would like.

The practical consequence for you is that neither a positive nor a negative headline transfers cleanly onto one patient. What transfers is the specific question of whether your presentation resembles the group that appeared to benefit, and whether anything about you — the stage, the tissue, the metabolic picture — argues against it. That is the conversation the appointment is for, and it is a more honest use of the evidence than quoting a summary statistic in either direction.

What Ballwin patients ask

I read that PRP does not work. Is that true?

For some indications and some preparations, the evidence is genuinely weak. For others it is reasonable. Lumping them together is the error: the explanation.

How do I judge a clinic?

Ask who performs it, whether it is image-guided, what preparation and dose, and what happens if it fails. Plain answers to those four separate most of the field.

Do you ever say no?

Regularly. The exclusions are set out before you drive rather than after.

How far is it from Ballwin?

About twenty-seven minutes north on I-270, near the outer edge of the area we serve.